アルファマンノシドーシスの世界市場レポート 2024

アルファマンノシドーシスの市場規模は、今後数年間で急速に成長すると予想されています。 2028年には18.0%の年間複合成長率（CAGR）で296億2,000万米ドルに成長すると予想されます。予測される成長は、世界の人口増加、都市化、eコマースの拡大、スポーツウェアの需要の増加、およびソーシャルメディアの普及による新興経済諸国での組織化された小売の台頭によって促進されます。主な動向としては、酵素療法の使用の増加、造血幹細胞移植の採用、および大槽注入の適用が挙げられます。

アルファマンノシドーシス市場で予想される成長は、希少疾患を対象とした医薬品承認に対する規制支援の増加によって促進されると予想されます。患者数が少ない病気の臨床試験を実施するという固有の課題は、規制上の取り組みを通じて解決されています。注目すべきは、2021年に米国食品医薬品局（FDA）が、限られた患者集団によってもたらされる困難を認識し、希少疾患の新たな治療法の開発と評価への支援を優先したことです。希少疾患に対処する医薬品に希少疾病用医薬品の指定を与えるFDAの権限は、条件を満たした臨床試験に対する税額控除、ユーザー手数料の免除、承認後7年間の市場独占権などのインセンティブをスポンサーに提供します。この規制の支援により、アルファマンノシドーシス市場を前進させる準備ができています。

アルファマンノシドーシス市場の成長は、ヘルスケア費の増加に大きく影響されます。ヘルスケア支出には、家族計画サービス、栄養プログラム、緊急医療援助、保健サービスに関連する費用が含まれます。政府の取り組み、助成金、奨励金は、アルファマンノシドーシスを含む希少疾患の分野で財政的支援を提供し、研究開発を奨励する上で重要な役割を果たします。たとえば、メディケア・メディケイド・サービスセンター（CMS）が2023年6月に発表したデータによると、米国の国民医療支出（NHE）は2021年に4兆3,000億米ドルに達し、国内総生産（GDP）の18.3％を占めました。このヘルスケア費の増加は、ヘルスケアへの取り組みを支援し、希少疾患の治療法の進歩に貢献するという取り組みを反映しています。その結果、ヘルスケア支出の増加がアルファマンノシドーシス市場を牽引すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のアルファマンノシドーシス市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 骨髄移植（BMT）
• 酵素補充療法（ERT）
• その他の治療
• 世界のアルファマンノシドーシス市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• タイプI
• タイプⅡ
• タイプⅢ
• 世界のアルファマンノシドーシス市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 専門クリニック

第7章 地域および国の分析

• 世界のアルファマンノシドーシス市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界のアルファマンノシドーシス市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• アルファマンノシドーシス市場の競合情勢
• アルファマンノシドーシス市場の企業プロファイル
  • Chiesi Farmaceutici SpA
  • Cipla
  • EdiGene Inc.
  • Immunochina
  • Takara Bio

第31章 その他の大手および革新的な企業

• Daiichi Sankyo Company
• Ultragenyx Pharmaceutical Inc
• Mitsubishi Tanabe Pharma
• Oxford Biomedica plc
• Santen Pharmaceutical Co.
• Merck
• GenScript
• Cellular Biomedicine Group
• GE Healthcare
• Lonza
• Nikon CeLL innovation Co. Ltd.
• Gilead Sciences
• Bristol-Myers Squibb
• Novartis AG
• Amgen

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Alpha mannosidosis is a rare genetic disorder characterized by the body's inability to effectively break down specific groups of complex sugars, leading to the accumulation of these sugars in various organs and systems, including the central nervous system. The impact of sugar buildup can vary significantly from person to person.

The primary therapeutic approaches for alpha mannosidosis include bone marrow transplant (BMT) and enzyme replacement therapy (ERT). A bone marrow transplant involves replacing dysfunctional marrow with healthy marrow to address the underlying genetic defect. Enzyme replacement therapy aims to supplement or replace a deficient enzyme in individuals lacking the enzyme or having a deficiency. The indications for alpha mannosidosis are classified into Type I, Type II, and Type III, and these therapeutic interventions are implemented across various healthcare settings, including hospitals and specialty clinics. These treatments play a crucial role in managing the symptoms and addressing the underlying genetic abnormalities associated with alpha mannosidosis.

The alpha mannosidosis market research report is one of a series of new reports from The Business Research Company that provides alpha mannosidosis market statistics, including alpha mannosidosis industry global market size, regional shares, competitors with an alpha mannosidosis market share, detailed alpha mannosidosis market segments, market trends and opportunities, and any further data you may need to thrive in the alpha mannosidosis industry. This alpha mannosidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alpha mannosidosis market size has grown rapidly in recent years. It will grow from $12.77 billion in 2023 to $15.26 billion in 2024 at a compound annual growth rate (CAGR) of 19.5%. The growth observed in the historical period can be attributed to several factors, including the expansion of emerging markets, urbanization trends, heightened demand for man-made fibers, and government initiatives supporting the textile industry.

The alpha mannosidosis market size is expected to see rapid growth in the next few years. It will grow to $29.62 billion in 2028 at a compound annual growth rate (CAGR) of 18.0%. The forecasted growth is fueled by global population growth, urbanization, e-commerce expansion, increased sportswear demand, and the rise of organized retail in developing economies, driven by social media penetration. Key trends include the growing use of enzyme therapy, adoption of hematopoietic stem cell transplantation, and the application of cisterna magna infusion.

The anticipated growth in the alpha mannosidosis market is expected to be driven by rising regulatory support for drug approval targeting rare diseases. The inherent challenge of conducting clinical trials for diseases with a small patient population is being addressed through regulatory initiatives. Notably, in 2021, the U.S. Food and Drug Administration (FDA) prioritized support for the development and evaluation of new treatments for rare diseases, recognizing the difficulties posed by limited patient populations. The FDA's authority to grant orphan drug designation for drugs addressing rare diseases provides sponsors with incentives such as tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval. This regulatory backing is poised to propel the alpha mannosidosis market forward.

The growth of the alpha mannosidosis market is significantly influenced by the increasing healthcare expenditure. Healthcare expenditure encompasses costs related to family planning services, nutrition programs, emergency medical assistance, and health services. Government initiatives, grants, and incentives play a crucial role in providing financial support and encouraging research and development in the field of rare diseases, including alpha mannosidosis. For instance, data released by the Centers for Medicare & Medicaid Services (CMS) in June 2023 indicates that the national health expenditure (NHE) in the United States reached $4.3 trillion in 2021, accounting for 18.3% of the Gross Domestic Product (GDP). This growing healthcare expenditure reflects a commitment to supporting healthcare initiatives, contributing to the advancement of treatments for rare diseases. Consequently, the increasing healthcare expenditure is expected to drive the alpha mannosidosis market.

Major companies in the alpha mannosidosis market are actively focused on developing enzyme replacement therapies to address rare alpha-mannosidosis. Enzyme replacement therapy involves supplying exogenous alpha-mannosidase, which helps reduce the accumulation of mannose-rich oligosaccharides in various tissues and organs, a characteristic feature of alpha-mannosidosis contributing to its pathological effects. A notable example is Chiesi Global Rare Diseases, a U.S.-based pharmaceutical company, which, in February 2023, launched Lamzede (velmanase alfa), the first enzyme replacement therapy authorized in the United States for treating alpha-mannosidosis. Lamzede acts similarly to the human body's alpha-mannosidase enzyme, restoring normal cellular activity in patients. The treatment involves a weekly injection of 10 mg of Lamzede.

The alpha mannosidosis market is further propelled by a significant surge in biopharmaceutical research and development (R&D) investments. The emphasis on R&D reflects the commitment of pharmaceutical companies and academic institutions to advancing innovative treatments for alpha mannosidosis. Advancements in genetic therapies and a deeper understanding of the molecular basis of alpha mannosidosis have contributed to the development of potential treatments. Examples of increased R&D investments include the UK government's announcement of a spending of $18.9 billion (£15.3 billion) in pharmaceutical R&D in 2020, with an allocated budget of $49.2 billion (£39.8 billion) for 2022-2025. Moreover, in March 2023, Merck, a Germany-based biopharmaceuticals manufacturer, reported a 3.9% increase in R&D spending for the year 2022 compared to 2021. Similarly, Roche Holding AG, a Switzerland-based biopharmaceuticals manufacturer, announced a 3.7% increase in R&D expenditure for the year 2022 compared to 2021. These increased investments in research and development by biopharmaceutical companies underscore the momentum driving the alpha mannosidosis market forward.

In April 2023, Italian pharmaceutical company Chiesi Farmaceutici acquired Amryt Pharma, a UK-based pharmaceutical company, for $1.25 billion. This strategic acquisition enhances Chiesi's Global Rare Diseases business division by incorporating Amryt Pharma's approved commercial products for rare diseases into its existing portfolio. Amryt Pharma is recognized for its dedication to developing and delivering innovative treatments for rare diseases.

Major companies operating in the alpha mannosidosis market report are Chiesi Farmaceutici S.p.A., Cipla, EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc., Mitsubishi Tanabe Pharma, Oxford Biomedica PLC, Santen Pharmaceutical Co., Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, Lonza, Nikon CeLL innovation Co. Ltd., Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Centogene, Zymenex A/S, Albumedix Ltd., Kite Pharma, Catalent, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Allergan, PsiOxus Therapeutics, Herantis Pharma PLC, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Bayer AG, Lyric Opera of Chicago, AMC Entertainment Holdings Inc., Regal Entertainment Group, Carmike Cinemas Inc., Ultragenyx, PTC Therapeutics, Gilead Sciences Inc., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Pfizer S.R.L., AstraZeneca PLC, Biotchpharma, Gene Vector Technologies, BrainStorm Cell Therapeutics, Pluristem, Biogen SA, Sanofi, Adcock Ingram

North America was the largest region in the alpha mannosidosis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the alpha mannosidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The alpha mannosidosis market includes revenues earned by entities by intellectual disability, skeletal abnormalities, hearing loss, and muscle weakness. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alpha Mannosidosis Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alpha mannosidosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alpha mannosidosis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The alpha mannosidosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Therapy Type: Bone Marrow Transplant (BMT); Enzyme Replacement Therapy (ERT); Other Therapies
• 2) By Indication: Type I; Type II; Type III
• 3) By End-User: Hospitals; Specialty Clinics
• Companies Mentioned: Chiesi Farmaceutici S.p.A.; Cipla; EdiGene Inc.; Immunochina; Takara Bio
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Alpha Mannosidosis Market Characteristics

3. Alpha Mannosidosis Market Trends And Strategies

4. Alpha Mannosidosis Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Alpha Mannosidosis Market Size and Growth

• 5.1. Global Alpha Mannosidosis Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Alpha Mannosidosis Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Alpha Mannosidosis Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Alpha Mannosidosis Market Segmentation

• 6.1. Global Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Bone Marrow Transplant (BMT)
• Enzyme Replacement Therapy (ERT)
• Other Therapies
• 6.2. Global Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Type I
• Type II
• Type III
• 6.3. Global Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics

7. Alpha Mannosidosis Market Regional And Country Analysis

• 7.1. Global Alpha Mannosidosis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Alpha Mannosidosis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Alpha Mannosidosis Market

• 8.1. Asia-Pacific Alpha Mannosidosis Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Alpha Mannosidosis Market

• 9.1. China Alpha Mannosidosis Market Overview
• 9.2. China Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Alpha Mannosidosis Market

• 10.1. India Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Alpha Mannosidosis Market

• 11.1. Japan Alpha Mannosidosis Market Overview
• 11.2. Japan Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Alpha Mannosidosis Market

• 12.1. Australia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Alpha Mannosidosis Market

• 13.1. Indonesia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Alpha Mannosidosis Market

• 14.1. South Korea Alpha Mannosidosis Market Overview
• 14.2. South Korea Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Alpha Mannosidosis Market

• 15.1. Western Europe Alpha Mannosidosis Market Overview
• 15.2. Western Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Alpha Mannosidosis Market

• 16.1. UK Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Alpha Mannosidosis Market

• 17.1. Germany Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Alpha Mannosidosis Market

• 18.1. France Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Alpha Mannosidosis Market

• 19.1. Italy Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Alpha Mannosidosis Market

• 20.1. Spain Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Alpha Mannosidosis Market

• 21.1. Eastern Europe Alpha Mannosidosis Market Overview
• 21.2. Eastern Europe Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Alpha Mannosidosis Market

• 22.1. Russia Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Alpha Mannosidosis Market

• 23.1. North America Alpha Mannosidosis Market Overview
• 23.2. North America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Alpha Mannosidosis Market

• 24.1. USA Alpha Mannosidosis Market Overview
• 24.2. USA Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Alpha Mannosidosis Market

• 25.1. Canada Alpha Mannosidosis Market Overview
• 25.2. Canada Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Alpha Mannosidosis Market

• 26.1. South America Alpha Mannosidosis Market Overview
• 26.2. South America Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Alpha Mannosidosis Market

• 27.1. Brazil Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Alpha Mannosidosis Market

• 28.1. Middle East Alpha Mannosidosis Market Overview
• 28.2. Middle East Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Alpha Mannosidosis Market

• 29.1. Africa Alpha Mannosidosis Market Overview
• 29.2. Africa Alpha Mannosidosis Market, Segmentation By Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Alpha Mannosidosis Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Alpha Mannosidosis Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Alpha Mannosidosis Market Competitive Landscape And Company Profiles

• 30.1. Alpha Mannosidosis Market Competitive Landscape
• 30.2. Alpha Mannosidosis Market Company Profiles
  • 30.2.1. Chiesi Farmaceutici S.p.A.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Cipla
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. EdiGene Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Immunochina
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Takara Bio
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Alpha Mannosidosis Market Other Major And Innovative Companies

• 31.1. Daiichi Sankyo Company
• 31.2. Ultragenyx Pharmaceutical Inc
• 31.3. Mitsubishi Tanabe Pharma
• 31.4. Oxford Biomedica plc
• 31.5. Santen Pharmaceutical Co.
• 31.6. Merck
• 31.7. GenScript
• 31.8. Cellular Biomedicine Group
• 31.9. GE Healthcare
• 31.10. Lonza
• 31.11. Nikon CeLL innovation Co. Ltd.
• 31.12. Gilead Sciences
• 31.13. Bristol-Myers Squibb
• 31.14. Novartis AG
• 31.15. Amgen

32. Global Alpha Mannosidosis Market Competitive Benchmarking

33. Global Alpha Mannosidosis Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Alpha Mannosidosis Market

35. Alpha Mannosidosis Market Future Outlook and Potential Analysis

• 35.1 Alpha Mannosidosis Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Alpha Mannosidosis Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Alpha Mannosidosis Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer